JP2025020148A5 - - Google Patents

Download PDF

Info

Publication number
JP2025020148A5
JP2025020148A5 JP2024179270A JP2024179270A JP2025020148A5 JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5 JP 2024179270 A JP2024179270 A JP 2024179270A JP 2024179270 A JP2024179270 A JP 2024179270A JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5
Authority
JP
Japan
Prior art keywords
receptor antagonist
crf
molecular weight
use according
low molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024179270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025020148A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/046760 external-priority patent/WO2019036503A1/en
Application filed filed Critical
Publication of JP2025020148A publication Critical patent/JP2025020148A/ja
Publication of JP2025020148A5 publication Critical patent/JP2025020148A5/ja
Pending legal-status Critical Current

Links

JP2024179270A 2017-08-14 2024-10-11 副腎皮質刺激ホルモン放出因子受容体拮抗薬 Pending JP2025020148A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545406P 2017-08-14 2017-08-14
US62/545,406 2017-08-14
PCT/US2018/046760 WO2019036503A1 (en) 2017-08-14 2018-08-14 CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP2019572817A JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2023146415A JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023146415A Division JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Publications (2)

Publication Number Publication Date
JP2025020148A JP2025020148A (ja) 2025-02-12
JP2025020148A5 true JP2025020148A5 (enExample) 2025-03-05

Family

ID=65362494

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019572817A Active JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2023146415A Active JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2024179270A Pending JP2025020148A (ja) 2017-08-14 2024-10-11 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019572817A Active JP7398963B2 (ja) 2017-08-14 2018-08-14 副腎皮質刺激ホルモン放出因子受容体拮抗薬
JP2023146415A Active JP7573080B2 (ja) 2017-08-14 2023-09-08 副腎皮質刺激ホルモン放出因子受容体拮抗薬

Country Status (11)

Country Link
US (9) US20210361664A1 (enExample)
EP (1) EP3628005A4 (enExample)
JP (3) JP7398963B2 (enExample)
KR (2) KR20200040761A (enExample)
CN (2) CN110996943A (enExample)
AU (2) AU2018317398A1 (enExample)
BR (1) BR112020002967A2 (enExample)
CA (1) CA3064464A1 (enExample)
EA (1) EA202090450A1 (enExample)
MX (2) MX2019015320A (enExample)
WO (1) WO2019036503A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296683B2 (en) 2014-01-21 2023-12-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CN112423747A (zh) * 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN120284862A (zh) 2018-12-07 2025-07-11 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
WO2021016208A1 (en) 2019-07-19 2021-01-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
CN116322544B (zh) 2020-08-12 2024-08-02 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
EP4203964A1 (en) * 2020-08-26 2023-07-05 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
CZ244598A3 (cs) 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
NZ333777A (en) 1996-07-24 2000-07-28 Du Pont Pharm Co (1,5-a) pyrazolo and triazole triazines and pyrimidines
ATE375344T1 (de) 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co Azolotriazine und pyrimidine
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
SI1344779T1 (sl) 1998-01-28 2006-02-28 Bristol Myers Squibb Pharma Co Azolo-pirimidini
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
PL354982A1 (en) 1999-09-30 2004-03-22 Neurogen Corporation Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
CN1679556A (zh) 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
IL157615A0 (en) 2001-03-13 2004-03-28 Bristol Myers Squibb Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
US20050085479A1 (en) 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
CA2547639A1 (en) 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
MY143499A (en) 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
EP1722826A2 (en) 2004-02-13 2006-11-22 SB Pharmco Puerto Rico Inc. Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
WO2005079807A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
KR20070120963A (ko) 2005-03-21 2007-12-26 일라이 릴리 앤드 캄파니 이미다조피리다진 화합물
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
CA2662000C (en) 2006-09-20 2013-01-08 Eli Lilly And Company Thiophene pyrazolopyrimidine compounds
ATE481405T1 (de) * 2006-09-20 2010-10-15 Lilly Co Eli Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
AR073708A1 (es) 2008-10-02 2010-11-24 Lilly Co Eli Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
US8153962B2 (en) * 2008-12-24 2012-04-10 Quest Diagnostics Investments Incorporated Mass spectrometry assay for congenital adrenal hyperplasia
EP2682111A1 (en) * 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
JP2015516979A (ja) 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
IL296683B2 (en) 2014-01-21 2023-12-01 Neurocrine Biosciences Inc Preparations for the treatment of congenital adrenal hyperplasia
WO2016161011A1 (en) 2015-03-31 2016-10-06 Ziva Medical, Inc. Methods and systems for the manipulation of ovarian tissues
EP3630763A4 (en) 2017-08-14 2021-03-10 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CN112423747A (zh) 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN120284862A (zh) 2018-12-07 2025-07-11 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
WO2021016208A1 (en) 2019-07-19 2021-01-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
CN116322544B (zh) 2020-08-12 2024-08-02 云杉生物科学公司 用于治疗多囊卵巢综合征的方法和组合物
JP2024539907A (ja) 2021-11-19 2024-10-31 スプルース バイオサイエンシーズ，インク． チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Similar Documents

Publication Publication Date Title
JP2025020148A5 (enExample)
Sitruk-Ware New progestagens for contraceptive use
Genazzani et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids
JP2656958B2 (ja) ホルモン依存性腫瘍治療剤
Sitruk-Ware et al. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills
CN102811730B (zh) 孕激素作为糖皮质激素增敏剂的使用
Sitruk-Ware et al. The use of newer progestins for contraception
Sitruk-Ware Pharmacology of different progestogens: the special case of drospirenone
Africander et al. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
Schindler et al. Reprint of classification and pharmacology of progestins
Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Fruzzetti et al. Review of clinical experience with estradiol in combined oral contraceptives
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
JP2013518908A5 (enExample)
IL286048B2 (en) Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation
CA2326654A1 (en) Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
Requena et al. Oral contraceptives in dermatology
Voutsadaki et al. Hypogonadism in adolescent girls: treatment and long-term effects
JPWO2021016208A5 (enExample)
Tatsumi et al. Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins
Fedotcheva et al. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application
JP2008534533A5 (enExample)
CN106232107A (zh) 用于抗孕激素的阴道递送的制剂和方法
Thomas et al. Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate α-ENaC and sgk1 expression in renal collecting duct epithelia
JP6343619B2 (ja) プロゲステロン依存性病態を処置する方法およびその組成物